{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:59:49Z","timestamp":1794650389570,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clinbiochem.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T20:58:58Z","timestamp":1682715538000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics"],"prefix":"10.1016","volume":"116","author":[{"given":"Yulian","family":"Mytsyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosyf","family":"Nakonechnyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Dosenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Pietrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Gazdikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Labudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Caprnda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Prosecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Dragasek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9010-1766","authenticated-orcid":false,"given":"Peter","family":"Kruzliak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Dats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2023.04.011_b0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0010","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/526341","article-title":"Kallikreins as Biomarkers for Prostate Cancer","volume":"2014","author":"Hong","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0020","unstructured":"R. Kirby, The role of PSA in detection and management of prostate cancer, Practitioner. 260 (2016) 17\u201321, 3."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0025","first-page":"120","article-title":"A Review on the Clinical Utility of PSA in Cancer Prostate, Indian","volume":"3","author":"Adhyam","year":"2012","journal-title":"J. Surg. Oncol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2023.04.011_b0030","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level \u22644.0 ng per Milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"68","author":"Arnsrud Godtman","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0040","first-page":"129","article-title":"Diagnosis of prostate cancer, Asian","volume":"6","author":"Descotes","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0050","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"STHLM3 consortium, MRI-Targeted or Standard Biopsy in Prostate Cancer Screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0055","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/JU.0000000000000185","article-title":"null Boris Zaslavsky, Clinical Validation of IsoPSATM, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer","volume":"201","author":"Stovsky","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0060","article-title":"Diagnosis accuracy of PCA3 level in patients with prostate cancer: a systematic review with meta-analysis","volume":"45","author":"Qin","year":"2019","journal-title":"Int. Braz. J. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eururo.2015.04.039","article-title":"Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment","volume":"70","author":"Tomlins","year":"2016","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.04.011_b0070","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","article-title":"Genomic Markers in Prostate Cancer Decision Making","volume":"73","author":"Cucchiara","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0075","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-0716-1354-2_9","article-title":"PCA3 in Prostate Cancer","volume":"2292","author":"Gunelli","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/cclm-2019-0693","article-title":"Biomarkers for prostate cancer: prostate-specific antigen and beyond","volume":"58","author":"Duffy","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0090","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euf.2018.01.010","article-title":"Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator","volume":"5","author":"Ankerst","year":"2019","journal-title":"Eur. Urol. Focus"},{"issue":"12","key":"10.1016\/j.clinbiochem.2023.04.011_b0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/pros.24182","article-title":"AEU-PIEM\/2018\/000 Investigators, Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-na\u00efve patients with clinical suspicion of prostate cancer who underwent the Select MDx test","volume":"81","author":"Lend\u00ednez\u2010Cano","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0100","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2007.11.038","article-title":"PCA3: a molecular urine assay for predicting prostate biopsy outcome","volume":"179","author":"Deras","year":"2008","journal-title":"J. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0105","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0115","first-page":"295","article-title":"Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma, Cent European","volume":"71","author":"Mytsyk","year":"2018","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.04.011_b0120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s11255-018-1841-x","article-title":"MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma","volume":"50","author":"Mytsyk","year":"2018","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-019-00574-7","article-title":"MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma","author":"Mytsyk","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0302-2838(03)00201-X","article-title":"DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer","volume":"44","author":"Hessels","year":"2003","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0135","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2013.52.8505","article-title":"Can urinary PCA3 supplement PSA in the early detection of prostate cancer?","volume":"32","author":"Wei","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0140","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2011.08.003","article-title":"Contemporary role of prostate cancer antigen 3 in the management of prostate cancer","volume":"60","author":"Auprich","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0145","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2010.11.044","article-title":"Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance","volume":"59","author":"Ploussard","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.clinbiochem.2023.04.011_b0150","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912023000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:00:27Z","timestamp":1757865627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912023000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":30,"alternative-id":["S0009912023000838"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.04.011","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}